Overview
- Novo Nordisk announced on Friday, July 31 that the phase 3 ZEUS trial in more than 6,300 people showed no reduction in major adverse cardiovascular events with ziltivekimab versus placebo (hazard ratio 0.99; 95% CI 0.88–1.11).
- The drug produced clear biological effects with expected drops in free interleukin‑6 and high‑sensitivity C‑reactive protein, confirming target engagement without translating into fewer heart attacks, strokes, or cardiovascular deaths.
- Overall rates of adverse events were similar between groups but a higher proportion of patients on ziltivekimab experienced serious infections while all‑cause mortality was unchanged.
- Investors reacted sharply with Novo Nordisk shares falling about 9% and the company said it will record a non‑cash impairment in Q3 2026 while keeping its previously stated adjusted operating profit outlook for 2026.
- Full ZEUS data will be presented at a scientific meeting and two other outcome trials of ziltivekimab (HERMES in heart failure and ARTEMIS post‑MI) will continue with headline readouts expected in the first half of 2027, leaving open whether different patient groups may benefit.